About Total Cancer Care
The Total Cancer Care research study will examine the unique molecular structures of different types of tumors and compare patients' responses to specific drug treatments to learn how to best treat each patient.
Technology has recently advanced to the point that researchers can now test each tumor for approximately 30,000 genes, which provide a molecular "fingerprint" unique to each tumor. Through Total Cancer Care, tumor tissues from thousands of patients across Florida will be collected and the biological markers unique to each tumor identified.
By studying those unique molecular structures and comparing patients’ responses to specific treatments, scientists hope to someday be able to develop new drug therapies that are personalized for each individual and the type of cancer he or she has. Scientists hope to learn which drugs work best in different patients in order to enhance the likelihood of patient improvement and reduce side-effects.
Who is Conducting this Research
Martin Health System, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute and M2Gen, is taking part in this innovative study along with other affiliated healthcare providers.
Located in Tampa, Fla., Moffitt Cancer Center is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer, as well as for ear, nose and throat. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.
Download the Total Cancer Care brochure.
Total Cancer Care Study
Disease Stage
NA
Status
Recruiting patients
Sponsor
M2GEN/Moffitt
Title
Study of genes in tumors to develop a molecular “fingerprint” for development of personalized therapies for each individual.
Phase
NA
Purpose
The purpose of this study is to collect and store clinical data and tissue from cancer patients to improve our ability to predict diagnosis, prognosis, and response to treatment in patients with cancer
Eligibility
Possible or proved cancer undergoing a surgical procedure that will allow enough tissue specimen for tumor banking.
Contact
772-288-5858, option 4
Contact Us
To learn more about this research, or find out how to participate, please contact:
Total Cancer Care™ clinical research coordinator
Robert and Carol Weissman Cancer Center
501 E. Osceola St.
Stuart, FL 34994
(772) 221-2060, or
(772) 223-5945, ext. 3699